Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2015. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility (PDMRs), or Connected Persons, in accordance with DTR 3.1.4 R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing discloses an increase in the notional allocation of GSK American Depositary Shares (ADSs) on May 14, 2015. This increase resulted from the revaluation of the cash element of the notional investment held within the GSK 401K plan. The transaction price was $44.99 per ADS.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Important Facts for Investors
- Transaction Date: May 14, 2015 (Notified May 15, 2015).
- Transaction Type: Increase in notional allocation of ADSs within the GSK 401K plan due to cash revaluation.
- Price: $44.99 per ADS.
- Individuals Involved:
- Mr W C Louv (Director): 22 ADSs
- Dr M M Slaoui (Director): 18 ADSs
- Dr K Slaoui (Connected Person): 17 ADSs